Search by Drug Name or NDC
NDC 00024-5761-01 Soliqua 100/33 100; 33 U/mL; ug/mL Details
Soliqua 100/33 100; 33 U/mL; ug/mL
Soliqua 100/33 is a SUBCUTANEOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by sanofi-aventis U.S. LLC. The primary component is INSULIN GLARGINE; LIXISENATIDE.
Product Information
| NDC | 00024-5761 |
|---|---|
| Product ID | 0024-5761_6c6933a6-cede-46c0-8140-7b59797b03d2 |
| Associated GPIs | 2799100235D220 |
| GCN Sequence Number | 076864 |
| GCN Sequence Number Description | insulin glargine/lixisenatide INSULN PEN 100-33/ML SUBCUT |
| HIC3 | C4X |
| HIC3 Description | ANTIHYPERGLY,INSULIN,LONG ACT-GLP-1 RECEPT.AGONIST |
| GCN | 42676 |
| HICL Sequence Number | 043944 |
| HICL Sequence Number Description | INSULIN GLARGINE,HUMAN RECOMBINANT ANALOG/LIXISENATIDE |
| Brand/Generic | Brand |
| Proprietary Name | Soliqua 100/33 |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | insulin glargine and lixisenatide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Active Ingredient Strength | 100; 33 |
| Active Ingredient Units | U/mL; ug/mL |
| Substance Name | INSULIN GLARGINE; LIXISENATIDE |
| Labeler Name | sanofi-aventis U.S. LLC |
| Pharmaceutical Class | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Insulin Analog [EPC], Insulin [CS] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA208673 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00024-5761-01 (00024576101)
| NDC Package Code | 0024-5761-01 |
|---|---|
| Billing NDC | 00024576101 |
| Package | 1 SYRINGE in 1 CARTON (0024-5761-01) / 3 mL in 1 SYRINGE |
| Marketing Start Date | 2016-11-21 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |